1
|
Monti G, Jensen ML, Mehmedbasic A, Jørgensen MM, Holm IE, Barkholt P, Zole E, Vægter CB, Vorum H, Nyengaard JR, Andersen OM. SORLA Expression in Synaptic Plexiform Layers of Mouse Retina. Mol Neurobiol 2020; 57:3106-3117. [PMID: 32472518 DOI: 10.1007/s12035-020-01946-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 05/13/2020] [Indexed: 11/25/2022]
Abstract
Sorting protein-related receptor containing LDLR class A repeats (SORLA; also known as LR11) exerts intraneuronal trafficking functions in the central nervous system. Recently, involvement of SORLA in retinogenesis was proposed, but no studies have examined yet in detail the expression pattern of this sorting receptor in the retina. Here, we provide a spatio-temporal characterization of SORL1 mRNA and its translational product SORLA in the postnatal mouse retina. Using stereological analysis, we confirmed previous studies showing that receptor depletion in knockout mice significantly reduces the number of cells in the inner nuclear layer (INL), suggesting that functional SORLA expression is essential for the development of this retinal strata. qPCR and Western blot analyses showed that SORL1/SORLA expression peaks at postnatal day 15, just after eye opening. Interestingly, we found that transcripts are somatically located in several neuronal populations residing in the INL and the ganglion cell layer, whereas SORLA protein is also present in the synaptic plexiform layers. In line with receptor expression in dendritic terminals, we found delayed stratification of the inner plexiform layer in knockout mice, indicating an involvement of SORLA in neuronal connectivity. Altogether, these data suggest a novel role of SORLA in synaptogenesis. Receptor dysfunctions may be implicated in morphological and functional impairments of retinal inner layer formation associated with eye disorders.
Collapse
Affiliation(s)
- Giulia Monti
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark
| | - Marianne L Jensen
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark
| | - Arnela Mehmedbasic
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark
| | - Margarita Melnikova Jørgensen
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.,Department of Pathology, Randers Regional Hospital, Randers, Denmark
| | - Ida E Holm
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.,Department of Pathology, Randers Regional Hospital, Randers, Denmark
| | - Pernille Barkholt
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark
| | - Egija Zole
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark
| | - Christian B Vægter
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark
| | - Henrik Vorum
- Department of Ophthalmology, Aalborg University Hospital, Hobrovej 18-22, DK-9000, Aalborg, Denmark
| | - Jens R Nyengaard
- Core Centre for Molecular Morphology, Section for Stereology and Microscopy, Department of Clinical Medicine, Centre for Stochastic Geometry and Advanced Bioimaging, Aarhus University, Aarhus, Denmark
| | - Olav M Andersen
- Danish Research Institute of Translational Neuroscience (DANDRITE) Nordic-EMBL Partnership, Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, DK-8000, Aarhus C, Denmark.
| |
Collapse
|
2
|
Ishida H, Jiang M, Ebinuma H, Hiruta N, Schneider WJ, Kinoshita T, Bujo H. Circulating soluble LR11, a differentiation regulator for vascular cells, is increased during pregnancy and exaggerated in patients with pre-eclampsia. Clin Chim Acta 2019; 497:172-177. [PMID: 31299181 DOI: 10.1016/j.cca.2019.07.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 06/13/2019] [Accepted: 07/01/2019] [Indexed: 01/02/2023]
Abstract
BACKGROUND Pre-eclampsia is a pregnancy-specific disease characterized by onset of hypertension and proteinuria, sometimes progressing into damaging other organs. Here, we investigated the pathological significance of the soluble fragment of LR11 (sLR11), a cell differentiation regulator, in comparison to circulating IL-6 and TNF-α, in pre-eclampsia. METHODS The study was conducted in a cross-sectional research design with fourteen pre-eclampsia patients and fifty healthy pregnant subjects. Pre-eclampsia was defined as hypertensive disorders in pregnancy at over 20 weeks of gestation with proteinuria. RESULTS Plasma levels of sLR11 as well as IL-6 in pre-eclampsia were increased compared with those in the healthy pregnant subjects at the first, the second, and the third trimester. Receiver operating characteristic analysis for the detection of pre-eclampsia among third-trimester subjects showed that the areas under the curves of sLR11 and IL-6 were equivalent. sLR11 and IL-6 correlated positively with TNF-α in healthy pregnant subjects. In the pre-eclampsia patients, there was neither a correlation between sLR11 and IL-6 nor between sLR11 and TNF-α. CONCLUSIONS sLR11 increases during pregnancy, with levels further exaggerated in pre-eclampsia, and may be related to the pathology of pre-eclampsia.
Collapse
Affiliation(s)
- Hiroaki Ishida
- Department of Obstetrics and Gynecology, Toho University Sakura Medical Center, Sakura, Japan
| | - Meizi Jiang
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan
| | - Hiroyuki Ebinuma
- Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan
| | - Nobuyuki Hiruta
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan; Department of Surgical Pathology, Toho University Sakura Medical Center, Sakura, Japan
| | - Wolfgang J Schneider
- Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University of Vienna, Vienna, Austria
| | - Toshihiko Kinoshita
- Department of Obstetrics and Gynecology, Toho University Sakura Medical Center, Sakura, Japan
| | - Hideaki Bujo
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan.
| |
Collapse
|
3
|
Du F, Li D, Piao LS, Yang KJ. Association of sLR11 gene polymorphism with T2DM and carotid atherosclerosis. Technol Health Care 2018; 26:391-400. [PMID: 29865095 DOI: 10.3233/thc-171040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Fei Du
- Department of Cell Biology and Medical Genetics, Yanbian University Medical College, Yanji, Jilin, China
| | - Dan Li
- Department of Endocrinology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China
| | - Lian-Shan Piao
- Department of Endocrinology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China
| | - Kang-Juan Yang
- Department of Cell Biology and Medical Genetics, Yanbian University Medical College, Yanji, Jilin, China
| |
Collapse
|
4
|
SorLA in Interleukin-6 Signaling and Turnover. Mol Cell Biol 2017; 37:MCB.00641-16. [PMID: 28265003 PMCID: PMC5440653 DOI: 10.1128/mcb.00641-16] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Accepted: 02/27/2017] [Indexed: 12/30/2022] Open
Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine with important functions in various physiologic processes. Mice lacking IL-6 exhibit multiple phenotypic abnormalities, such as an inadequate immune and acute-phase response, and elevated levels of circulating IL-6 have been found to accompany several pathological conditions. IL-6 binds the nonsignaling IL-6 receptor (IL-6R), which is expressed as a transmembrane, as well as a secreted circulating protein, before it engages homodimeric gp130 for signaling. Complex formation between IL-6 and the membrane-bound IL-6 receptor gives rise to classic cis signaling, whereas complex formation between IL-6 and the soluble IL-6R results in trans signaling. Here, we report that the endocytic receptor SorLA targets IL-6 and IL-6R. We present evidence that SorLA mediates efficient cellular uptake of both IL-6 and the circulating IL-6R in astrocytes. We further show that SorLA interacts with the membrane-bound IL-6R at the cell surface and thereby downregulates IL-6 cis signaling. Finally, we find that the SorLA ectodomain, released from the cell membrane upon enzymatic cleavage of full-length SorLA, may act as an IL-6 carrier protein that stabilizes IL-6 and its capacity for trans signaling.
Collapse
|
5
|
Tien WS, Chen JH, Wu KP. SheddomeDB: the ectodomain shedding database for membrane-bound shed markers. BMC Bioinformatics 2017; 18:42. [PMID: 28361715 PMCID: PMC5374707 DOI: 10.1186/s12859-017-1465-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND A number of membrane-anchored proteins are known to be released from cell surface via ectodomain shedding. The cleavage and release of membrane proteins has been shown to modulate various cellular processes and disease pathologies. Numerous studies revealed that cell membrane molecules of diverse functional groups are subjected to proteolytic cleavage, and the released soluble form of proteins may modulate various signaling processes. Therefore, in addition to the secreted protein markers that undergo secretion through the secretory pathway, the shed membrane proteins may comprise an additional resource of noninvasive and accessible biomarkers. In this context, identifying the membrane-bound proteins that will be shed has become important in the discovery of clinically noninvasive biomarkers. Nevertheless, a data repository for biological and clinical researchers to review the shedding information, which is experimentally validated, for membrane-bound protein shed markers is still lacking. RESULTS In this study, the database SheddomeDB was developed to integrate publicly available data of the shed membrane proteins. A comprehensive literature survey was performed to collect the membrane proteins that were verified to be cleaved or released in the supernatant by immunological-based validation experiments. From 436 studies on shedding, 401 validated shed membrane proteins were included, among which 199 shed membrane proteins have not been annotated or validated yet by existing cleavage databases. SheddomeDB attempted to provide a comprehensive shedding report, including the regulation of shedding machinery and the related function or diseases involved in the shedding events. In addition, our published tool ShedP was embedded into SheddomeDB to support researchers for predicting the shedding event on unknown or unrecorded membrane proteins. CONCLUSIONS To the best of our knowledge, SheddomeDB is the first database for the identification of experimentally validated shed membrane proteins and currently may provide the most number of membrane proteins for reviewing the shedding information. The database included membrane-bound shed markers associated with numerous cellular processes and diseases, and some of these markers are potential novel markers because they are not annotated or validated yet in other databases. SheddomeDB may provide a useful resource for discovering membrane-bound shed markers. The interactive web of SheddomeDB is publicly available at http://bal.ym.edu.tw/SheddomeDB/ .
Collapse
Affiliation(s)
- Wei-Sheng Tien
- Institute of Biomedical Informatics, National Yang Ming University, Taipei, 112, Taiwan.,Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, Taipei, 115, Taiwan
| | - Jun-Hong Chen
- Department of Computer Science, National Taipei University of Education, Taipei, 106, Taiwan
| | - Kun-Pin Wu
- Institute of Biomedical Informatics, National Yang Ming University, Taipei, 112, Taiwan.
| |
Collapse
|
6
|
Soluble form of LR11 is highly increased in the vitreous fluids of patients with idiopathic epiretinal membrane. Graefes Arch Clin Exp Ophthalmol 2017; 255:885-891. [DOI: 10.1007/s00417-017-3585-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 12/24/2016] [Accepted: 01/04/2017] [Indexed: 12/11/2022] Open
|
7
|
Ponsuksili S, Trakooljul N, Hadlich F, Haack F, Murani E, Wimmers K. Genetically regulated hepatic transcripts and pathways orchestrate haematological, biochemical and body composition traits. Sci Rep 2016; 6:39614. [PMID: 28000754 PMCID: PMC5175187 DOI: 10.1038/srep39614] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Accepted: 11/22/2016] [Indexed: 01/19/2023] Open
Abstract
The liver is the central metabolic organ and exhibits fundamental functions in haematological traits. Hepatic expression, haematological, plasma biochemical, and body composition traits were assessed in a porcine model (n = 297) to establish tissue-specific genetic variations that influence the function of immune-metabolism-correlated expression networks. At FDR (false discovery rate) <1%, more than 3,600 transcripts were jointly correlated (r = |0.22-0.48|) with the traits. Functional enrichment analysis demonstrated common links of metabolic and immune traits. To understand how immune and metabolic traits are affected via genetic regulation of gene expression, eQTLs were assessed. 20517 significant (FDR < 5%) eQTLs for 1401 transcripts were identified, among which 443 transcripts were associated with at least one of the examined traits and had cis-eQTL (such as ACO1 (6.52 × 10-7) and SOD1 (6.41 × 10-30). The present study establishes a comprehensive view of hepatic gene activity which links together metabolic and immune traits in a porcine model for medical research.
Collapse
Affiliation(s)
- Siriluck Ponsuksili
- Research Unit 'Functional Genome Analysis', Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany
| | - Nares Trakooljul
- Research Unit 'Genomics', Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany
| | - Frieder Hadlich
- Research Unit 'Functional Genome Analysis', Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany
| | - Fiete Haack
- Research Unit 'Functional Genome Analysis', Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany
| | - Eduard Murani
- Research Unit 'Genomics', Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany
| | - Klaus Wimmers
- Research Unit 'Genomics', Leibniz Institute for Farm Animal Biology (FBN), Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany
| |
Collapse
|
8
|
Levels of the soluble LDL receptor-relative LR11 decrease in overweight individuals with type 2 diabetes upon diet-induced weight loss. Atherosclerosis 2016; 254:67-72. [DOI: 10.1016/j.atherosclerosis.2016.09.066] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Revised: 09/15/2016] [Accepted: 09/22/2016] [Indexed: 12/31/2022]
|
9
|
Jiang L, Konishi H, Nurwidya F, Satoh K, Takahashi F, Ebinuma H, Fujimura K, Takasu K, Jiang M, Shimokawa H, Bujo H, Daida H. Deletion of LR11 Attenuates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation With Medial Thickening in Mice. Arterioscler Thromb Vasc Biol 2016; 36:1972-9. [PMID: 27493099 DOI: 10.1161/atvbaha.116.307900] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Accepted: 07/19/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVE We aimed to determine whether LR11 (low-density lipoprotein receptor with 11 binding repeats) is a potential key regulator of smooth muscle cell (SMC) proliferation during the progression of hypoxia-induced medial thickening in mice and whether sLR11 (soluble LR11) can serve as a biomarker in patients with pulmonary arterial hypertension. APPROACH AND RESULTS The role of LR11 in pulmonary arterial hypertension was investigated using mouse and cell models of induced hypoxia. The expression of LR11 and of hypoxia-inducible factor-1α was significantly increased in lung tissues from C57Bl/6 mice after 3 weeks of exposure to hypoxia compared with normoxia. Serum sLR11 levels were also increased. Physiological and histochemical analyses showed that increased right ventricular systolic pressure, right ventricular hypertrophy, and medial thickening induced under hypoxia in wild-type mice were attenuated in LR11(-/-) mice. The proliferation rates stimulated by hypoxia or platelet-derived growth factor-BB were attenuated in SMC derived from LR11(-/-) mice, compared with those from wild-type mice. Exogenous sLR11 protein increased the proliferation rates of SMC from wild-type mice. The expression of LR11 and hypoxia-inducible factor-1α was increased in cultured SMC under hypoxic conditions, and hypoxia-inducible factor-1α knockdown almost abolished the induction of LR11. Serum sLR11 levels were significantly higher in patients with, rather than without, pulmonary arterial hypertension. sLR11 levels positively correlated with pulmonary vascular resistance and mean pulmonary arterial pressure. CONCLUSIONS LR11 regulated SMC proliferation during the progression of hypoxia-induced medial thickening in mice. The findings obtained from mice, together with those in humans, indicate that sLR11 could serve as a novel biomarker that reflects the pathophysiology of proliferating medial SMC in pulmonary arterial hypertension.
Collapse
Affiliation(s)
- Le Jiang
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Hakuoh Konishi
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.).
| | - Fariz Nurwidya
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Kimio Satoh
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Fumiyuki Takahashi
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Hiroyuki Ebinuma
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Kengo Fujimura
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Kiyoshi Takasu
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Meizi Jiang
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Hiroaki Shimokawa
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Hideaki Bujo
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| | - Hiroyuki Daida
- From the Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (L.J., H.K., K.T., H.D.); Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (F.N., F.T.); Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.S., H.S.); Tsukuba Research Institute, Sekisui Medical Co Ltd, Ryugasaki, Japan (H.E., K.F.); and Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Sakura Medical Center, Sakura, Japan (M.J., H.B.)
| |
Collapse
|
10
|
Circulating soluble form of LR11, a regulator of smooth muscle cell migration, is a novel marker for intima-media thickness of carotid arteries in type 2 diabetes. Clin Chim Acta 2016; 457:137-41. [PMID: 27095609 DOI: 10.1016/j.cca.2016.04.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Revised: 03/18/2016] [Accepted: 04/14/2016] [Indexed: 01/17/2023]
Abstract
BACKGROUND Smooth muscle cell (SMC) migration from the media to the intima, a process affecting plaque stability in advanced-stage atherosclerosis, is under the control of LR11. To delineate the clinical significance of the circulating soluble form of LR11 (sLR11) in patients with type 2 diabetes (T2D), we analyzed the correlation of sLR11 levels with intima-media thickness (IMT) of carotid arteries. METHODS Plasma sLR11 levels were measured in 165 patients with T2D (mean age 56.2±10.4 y, 58.2% males, and BMI 24.6±3.6) by ELISA. Averaged IMT levels of common carotid arteries were determined by ultrasonography. RESULTS Circulating sLR11 levels were 9.8±3.5ng/ml, and correlated positively with the classical atherosclerosis risk factors age, sex, systolic blood pressure, low-density lipoprotein-cholesterol (LDL-C), fasting plasma-glucose (FPG), and glycosylated hemoglobin. Multivariate linear regression analysis indicated that only FPG was associated with sLR11; sLR11 correlated positively with IMT, together with age and FPG, but less with LDL-C. Among the serum risk factors for IMT, multivariate linear regression analysis uncovered that sLR11 was independently associated with IMT. Subsequent logistic analysis revealed that FPG correlated best with IMT values at a cut-off of 0.80mm and sLR11 at a cut-off of 0.90mm, respectively, while LDL-C showed lower discriminatory power at any IMT cut-off values. CONCLUSION Increased sLR11 concentrations are highly associated with increased IMT as well as with FPG in middle-aged, non-obese patients with T2D. Circulating sLR11 may be a novel marker representing the pathophysiology of intimal SMCs in patients with T2D.
Collapse
|
11
|
Tsukamoto S, Takeuchi M, Kawaguchi T, Togasaki E, Yamazaki A, Sugita Y, Muto T, Sakai S, Takeda Y, Ohwada C, Sakaida E, Shimizu N, Nishii K, Jiang M, Yokote K, Bujo H, Nakaseko C. Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. Exp Mol Med 2014; 46:e89. [PMID: 24699135 PMCID: PMC3944444 DOI: 10.1038/emm.2013.161] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Revised: 11/10/2013] [Accepted: 11/25/2013] [Indexed: 02/05/2023] Open
Abstract
LR11, also known as SorLA or SORL1, is a type-I membrane protein from which a large extracellular part, soluble LR11 (sLR11), is released by proteolytic shedding on cleavage with a disintegrin and metalloproteinase 17 (ADAM17). A shedding mechanism is presumed to have a key role in the functions of LR11, but the evidence for this has not yet been demonstrated. Tetraspanin CD9 has been recently shown to regulate the ADAM17-mediated shedding of tumor necrosis factor-α and intercellular adhesion molecule-1 on the cell surface. Here, we investigated the role of CD9 on the shedding of LR11 in leukocytes. LR11 was not expressed in THP-1 monocytes, but it was expressed and released in phorbol 12-myristate 13-acetate (PMA)-induced THP-1 macrophages (PMA/THP-1). Confocal microscopy showed colocalization of LR11 and CD9 proteins on the cell surface of PMA/THP-1. Ectopic neo-expression of CD9 in CCRF-SB cells, which are LR11-positive and CD9-negative, reduced the amount of sLR11 released from the cells. In contrast, incubation of LR11-transfected THP-1 cells with neutralizing anti-CD9 monoclonal antibodies increased the amount of sLR11 released from the cells. Likewise, the PMA-stimulated release of sLR11 increased in THP-1 cells transfected with CD9-targeted shRNAs, which was negated by treatment with the metalloproteinase inhibitor GM6001. These results suggest that the tetraspanin CD9 modulates the ADAM17-mediated shedding of LR11 in various leukemia cell lines and that the association between LR11 and CD9 on the cell surface has an important role in the ADAM17-mediated shedding mechanism.
Collapse
Affiliation(s)
- Shokichi Tsukamoto
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Masahiro Takeuchi
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Takeharu Kawaguchi
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Emi Togasaki
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Atsuko Yamazaki
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Yasumasa Sugita
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Tomoya Muto
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Shio Sakai
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan [3] Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan
| | - Yusuke Takeda
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Chikako Ohwada
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Emiko Sakaida
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Naomi Shimizu
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan [3] Division of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan
| | - Keigo Nishii
- Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Meizi Jiang
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Medical Center Sakura Hospital, Sakura, Japan
| | - Koutaro Yokote
- Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Hideaki Bujo
- Department of Clinical-Laboratory and Experimental-Research Medicine, Toho University Medical Center Sakura Hospital, Sakura, Japan
| | - Chiaki Nakaseko
- 1] Department of Hematology, Chiba University Hospital, Chiba, Japan [2] Department of Clinical Cell Biology and Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan
| |
Collapse
|
12
|
Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, Takeuchi M, Sakaida E, Jiang M, Nakaseko C, Bujo H. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma. Clin Chim Acta 2014; 430:48-54. [DOI: 10.1016/j.cca.2013.12.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 12/18/2013] [Accepted: 12/26/2013] [Indexed: 11/26/2022]
|
13
|
Shimizu N, Nakaseko C, Jiang M, Nishii K, Yokote K, Iseki T, Higashi M, Tamaru J, Schneider WJ, Bujo H. G-CSF induces the release of the soluble form of LR11, a regulator of myeloid cell mobilization in bone marrow. Ann Hematol 2014; 93:1111-22. [DOI: 10.1007/s00277-014-2033-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Accepted: 02/06/2014] [Indexed: 12/21/2022]
|
14
|
Vitreous fluid and circulating levels of soluble lr11, a novel marker for progression of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2013; 251:2689-95. [DOI: 10.1007/s00417-013-2373-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Revised: 04/06/2013] [Accepted: 04/25/2013] [Indexed: 10/26/2022] Open
|